☰

Jason S. Lewis - Publications

Affiliations: 
Radiological Sciences Washington University School of Medicine, St. Louis, MO, United States 
Tree Info Similar researchers PubMed Report error

275 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Mack KN, Samuels ZV, Carter LM, Viray TD, Mandleywala K, Brooks CL, Hollingsworth MA, Radhakrishnan P, Lewis JS. Interrogating the Theranostic Capacity of a MUC16-Targeted Antibody for Ovarian Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 38485271 DOI: 10.2967/jnumed.123.266524  0.319
2022 Bauer D, Visca H, Weerakkody A, Carter LM, Samuels Z, Kaminsky S, Andreev OA, Reshetnyak YK, Lewis JS. PET Imaging of Acidic Tumor Environment With Zr-labeled pHLIP Probes. Frontiers in Oncology. 12: 882541. PMID 35664740 DOI: 10.3389/fonc.2022.882541  0.314
2020 Mandleywala K, Shmuel S, Pereira PMR, Lewis JS. Antibody-Targeted Imaging of Gastric Cancer. Molecules (Basel, Switzerland). 25. PMID 33050602 DOI: 10.3390/molecules25204621  0.302
2020 Brito A, Pereira PMR, Reis RL, Ulijn RV, Lewis JS, Pires RA, Pashkuleva I. Aromatic carbohydrate amphiphile disrupts cancer spheroids and prevents relapse. Nanoscale. 12: 19088-19092. PMID 32955076 DOI: 10.1039/D0Nr05008C  0.302
2020 Hernández-Gil J, Lewis JS, Reiner T, Drain CM, Gonzales J. Leveraging synthetic chlorins for bio-imaging applications. Chemical Communications (Cambridge, England). PMID 32945820 DOI: 10.1039/D0Cc05494A  0.348
2020 Sobol NB, Korsen JA, Younes A, Edwards KJ, Lewis JS. ImmunoPET Imaging of Pancreatic Tumors with Zr-Labeled Gold Nanoparticle-Antibody Conjugates. Molecular Imaging and Biology. PMID 32909244 DOI: 10.1007/S11307-020-01535-3  0.335
2020 Ulaner GA, Jhaveri K, Chardarlapaty S, Hatzoglou V, Riedl C, Lewis JS, Mauguen A. Head-to-head evaluation of F-FES and F-FDG PET/CT in metastatic invasive lobular breast cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 32680923 DOI: 10.2967/Jnumed.120.247882  0.33
2020 Pereira PMR, Norfleet J, Lewis JS, Escorcia FE. ImmunoPET Detects Changes in Multi-RTK Tumor Cell Expression Levels in Response to Targeted Kinase Inhibition. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 32646879 DOI: 10.2967/Jnumed.120.244897  0.332
2020 Fung K, Sharma SK, Keinänen O, Long Roche K, Lewis JS, Zeglis BM. A Molecularly Targeted Intraoperative Near-Infrared Fluorescence Imaging Agent for High Grade Serous Ovarian Cancer. Molecular Pharmaceutics. PMID 32644804 DOI: 10.1021/Acs.Molpharmaceut.0C00437  0.361
2020 Ulaner GA, Carrasquillo JA, Riedl CC, Yeh R, Hatzoglou V, Ross DS, Jhaveri K, Chandarlapaty S, Hyman DM, Zeglis BM, Lyashchenko SK, Lewis JS. Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted Zr-Pertuzumab PET/CT. Radiology. 192828. PMID 32515679 DOI: 10.1148/Radiol.2020192828  0.339
2020 Poty S, Mandleywala K, O'Neill E, Knight JC, Cornelissen B, Lewis JS. Zr-PET imaging of DNA double-strand breaks for the early monitoring of response following α- and β-particle radioimmunotherapy in a mouse model of pancreatic ductal adenocarcinoma. Theranostics. 10: 5802-5814. PMID 32483420 DOI: 10.7150/Thno.44772  0.386
2020 Nemieboka B, Sharma SK, Rao TD, Edwards KJ, Yan S, Wang P, Ragupathi A, Piersigilli A, Spriggs DR, Lewis JS. Radiopharmacologic screening of antibodies to the unshed ectodomain of MUC16 in ovarian cancer identifies a lead candidate for clinical translation. Nuclear Medicine and Biology. 86: 9-19. PMID 32403071 DOI: 10.1016/J.Nucmedbio.2020.04.006  0.322
2020 Krebs S, O'Donoghue JA, Biegel E, Beattie BJ, Reidy D, Lyashchenko SK, Lewis JS, Bodei L, Weber WA, Pandit-Taskar N. Comparison of Ga-DOTA-JR11 PET/CT with dosimetric Lu-satoreotide tetraxetan (Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging. PMID 32378020 DOI: 10.1007/S00259-020-04832-9  0.375
2020 Dunphy MP, Pressl C, Pillarsetty N, Grkovski M, Modi S, Jhaveri K, Norton L, Beattie BJ, Zanzonico PB, Zatorska D, Taldone T, Ochiana SO, Uddin MM, Burnazi EM, Lyashchenko SK, ... Lewis JS, et al. First-in-Human Trial of Epichaperome-Targeted Positron Emission Tomography in Cancer Patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32366671 DOI: 10.1158/1078-0432.Ccr-19-3704  0.415
2020 Ulaner GA, Sobol NB, O'Donoghue JA, Kirov AS, Riedl CC, Min R, Smith E, Carter LM, Lyashchenko SK, Lewis JS, Landgren CO. CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging. Radiology. 192621. PMID 32255416 DOI: 10.1148/Radiol.2020192621  0.373
2020 Goos JACM, Davydova M, Lengkeek N, Greguric I, Whittaker MR, Quinn JF, Baell JB, Lewis JS, Davis TP. pH-Responsive Polymers for Improving the Signal-to-Noise Ratio of Hypoxia PET Imaging with [ F]Fluoromisonidazole. Macromolecular Rapid Communications. e2000061. PMID 32250004 DOI: 10.1002/Marc.202000061  0.339
2020 Schöder HM, Demétrio De Souza França P, Nakajima R, Burnazi EM, Roberts S, Brand C, Grkovski M, Mauguen A, Dunphy MP, Ghossein R, Lyashchenko SK, Lewis JS, O'Donoghue JA, Ganly I, Patel SG, et al. Safety and feasibility of PARP1/2 imaging with 18F-PARPi in patients with head and neck cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32245901 DOI: 10.1158/1078-0432.Ccr-19-3484  0.347
2020 Sharma SK, Glaser JM, Edwards KJ, Khozeimeh Sarbisheh E, Salih AK, Lewis JS, Price EW. A Systematic Evaluation of Antibody Modification and 89Zr-Radiolabeling for Optimized Immuno-PET. Bioconjugate Chemistry. PMID 32197571 DOI: 10.1021/Acs.Bioconjchem.0C00087  0.335
2020 Krebs S, Veach DR, Carter LM, Grkovski M, Fornier M, Mauro MJ, Voss MH, Danila DC, Burnazi E, Null M, Staton K, Pressl C, Beattie BJ, Zanzonico PB, Weber WA, ... Lewis JS, et al. First-in-Human Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted Positron Emission Tomography. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 32169913 DOI: 10.2967/Jnumed.119.234864  0.388
2020 Goos JACM, Davydova M, Dilling TR, Cho A, Cornejo MA, Gupta A, Price WS, Puttick S, Whittaker MR, Quinn JF, Davis TP, Lewis JS. Design and preclinical evaluation of nanostars for the passive pretargeting of tumor tissue. Nuclear Medicine and Biology. 84: 63-72. PMID 32135473 DOI: 10.1016/J.Nucmedbio.2020.02.012  0.367
2020 Pereira PMR, Edwards KJ, Mandleywala K, Carter LM, Escorcia FE, Campesato LF, Cornejo M, Abma L, Mohsen AA, Iacobuzio-Donahue CA, Merghoub T, Lewis JS. iNOS regulates the therapeutic response of pancreatic cancer cells to radiation therapy. Cancer Research. PMID 32086240 DOI: 10.1158/0008-5472.Can-19-2991  0.335
2020 Pirovano G, Jannetti SA, Carter LM, Sadique A, Kossatz S, Guru N, Demétrio De Souza França P, Maeda M, Zeglis BM, Lewis JS, Humm JL, Reiner T. Targeted brain tumor radiotherapy using an Auger emitter. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32066626 DOI: 10.1158/1078-0432.Ccr-19-2440  0.31
2020 Vivier D, Fung K, Rodriguez C, Adumeau P, Ulaner GA, Lewis JS, Sharma SK, Zeglis BM. The Influence of Glycans-Specific Bioconjugation on the FcγRI Binding and Performance of Zr-DFO-Pertuzumab. Theranostics. 10: 1746-1757. PMID 32042334 DOI: 10.7150/Thno.39089  0.305
2020 Pereira PMR, Roberts S, Figueira F, Tome JPC, Reiner T, Lewis JS. PET/CT imaging with a F-labeled galactodendritic unit in a galectin-1 overexpressing orthotopic bladder cancer model. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 32005776 DOI: 10.2967/Jnumed.119.236430  0.406
2020 Henry KE, Chaney AM, Nagle VL, Cropper HC, Mozaffari S, Slaybaugh G, Parang K, Andreev O, Reshetnyak YK, James ML, Lewis JS. Demarcation of Sepsis-Induced Peripheral and Central Acidosis with pH-Low Insertion Cyclic (pHLIC) Peptide. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 32005774 DOI: 10.2967/Jnumed.119.233072  0.346
2020 Goos JACM, Cho A, Carter LM, Dilling TR, Davydova M, Mandleywala K, Puttick S, Gupta A, Price WS, Quinn JF, Whittaker MR, Lewis JS, Davis TP. Delivery of polymeric nanostars for molecular imaging and endoradiotherapy through the enhanced permeability and retention (EPR) effect. Theranostics. 10: 567-584. PMID 31903138 DOI: 10.7150/Thno.36777  0.352
2020 Escorcia FE, Houghton JL, Abdel-Atti D, Pereira PR, Cho A, Gutsche NT, Baidoo KE, Lewis JS. ImmunoPET Predicts Response to Met-targeted Radioligand Therapy in Models of Pancreatic Cancer Resistant to Met Kinase Inhibitors. Theranostics. 10: 151-165. PMID 31903112 DOI: 10.7150/Thno.37098  0.347
2019 Pereira PMR, Ragupathi A, Shmuel S, Mandleywala K, Viola NT, Lewis JS. HER2-targeted PET imaging and therapy of hyaluronan-masked HER2-overexpressing breast cancer. Molecular Pharmaceutics. PMID 31804840 DOI: 10.1021/Acs.Molpharmaceut.9B01091  0.355
2019 Lewis JS, Membreno R. Correction to: The 2019 World Molecular Imaging Congress (WMIC) and Molecular Imaging and Biology (MIB) Awards. Molecular Imaging and Biology. PMID 31802360 DOI: 10.1007/S11307-019-01457-9  0.302
2019 Sarparanta M, Pourat J, Carnazza KE, Tang J, Paknejad N, Reiner T, Kostiainen MA, Lewis JS. Multimodality labeling strategies for the investigation of nanocrystalline cellulose biodistribution in a mouse model of breast cancer. Nuclear Medicine and Biology. 80: 1-12. PMID 31759312 DOI: 10.1016/J.Nucmedbio.2019.11.002  0.371
2019 Lewis JS, Membreno R. The 2019 World Molecular Imaging Congress (WMIC) and Molecular Imaging and Biology (MIB) Awards. Molecular Imaging and Biology. PMID 31667716 DOI: 10.1007/S11307-019-01444-0  0.306
2019 Pandit-Taskar N, Postow M, Hellmann M, Harding J, Barker C, O'Donoghue J, Ziolkowska M, Ruan S, Lyashchenko S, Tsai F, Farwell M, Mitchell T, Korn R, Le W, Lewis J, et al. First-in-human imaging with Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion targeting. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 31586002 DOI: 10.2967/Jnumed.119.229781  0.354
2019 Lohrmann C, O'Reilly EM, O'Donoghue JA, Pandit-Taskar N, Carrasquillo JA, Lyashchenko SK, Ruan S, Teng R, Scholz WW, Maffuid PW, Lewis JS, Weber WA. Retooling a Blood-based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of Pancreatic Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31540979 DOI: 10.1158/1078-0432.Ccr-18-3667  0.332
2019 Reidy-Lagunes D, Pandit-Taskar N, O'Donoghue JA, Krebs S, Staton KD, Lyashchenko SK, Lewis JS, Raj N, Gonen M, Lohrmann C, Bodei L, Weber WA. Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177 Lu-Satoreotide Tetraxetan. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31439583 DOI: 10.1158/1078-0432.Ccr-19-1026  0.311
2019 Mason C, Kossatz S, Carter L, Pirovano G, Brand C, Guru N, Pérez-Medina C, Lewis JS, Mulder W, Reiner T. A Zr-HDL PET tracer monitors response to a CSF1R inhibitor. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 31420495 DOI: 10.2967/Jnumed.119.230466  0.378
2019 Pandit-Taskar N, Zanzonico PB, Kramer K, Grkovski M, Fung EK, Shi W, Zhang Z, Lyashchenko SK, Vietri SM, Fung AM, Pentlow KS, Carrasquillo JA, Lewis JS, Larson SM, Cheung NV, et al. Biodistribution and Dosimetry of Intraventricularly Administered I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 31405921 DOI: 10.2967/Jnumed.118.219576  0.321
2019 Bhupathiraju NVSDK, Younes A, Cao M, Ali J, Cicek HT, Tully KM, Ponnala S, Babich JW, Deri MA, Lewis JS, Francesconi LC, Drain CM. Improved synthesis of the bifunctional chelator p-SCN-Bn-HOPO. Organic & Biomolecular Chemistry. PMID 31268109 DOI: 10.1039/C9Ob01068H  0.378
2019 Roberts S, Strome A, Choi C, Andreou C, Kossatz S, Brand C, Williams T, Bradbury M, Kircher MF, Reshetnyak YK, Grimm J, Lewis JS, Reiner T. Acid specific dark quencher QC1 pHLIP for multi-spectral optoacoustic diagnoses of breast cancer. Scientific Reports. 9: 8550. PMID 31189972 DOI: 10.1038/S41598-019-44873-1  0.315
2019 Pereira PM, Mandleywala K, Ragupathi A, Carter LM, Goos JACM, Janjigian YY, Lewis JS. Temporal Modulation of HER2 Membrane Availability Increases Pertuzumab Uptake and Pretargeted Molecular Imaging of Gastric Tumors. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 31171598 DOI: 10.2967/Jnumed.119.225813  0.397
2019 Lobatto ME, Binderup T, Robson PM, Giesen LFP, Calcagno C, Witjes J, Fay F, Baxter S, Wessel CH, Eldib M, Bini J, Carlin SD, Stroes ESG, Storm G, Kjær A, Lewis JS, et al. Multimodal positron emission tomography imaging to quantify uptake of 89Zr-labeled liposomes in the atherosclerotic vessel wall. Bioconjugate Chemistry. PMID 31095372 DOI: 10.1021/Acs.Bioconjchem.9B00256  0.36
2019 Carter LM, Kesner AL, Pratt EC, Sanders VA, Massicano AVF, Cutler CS, Lapi SE, Lewis JS. The Impact of Positron Range on PET Resolution, Evaluated with Phantoms and PHITS Monte Carlo Simulations for Conventional and Non-conventional Radionuclides. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. PMID 31001765 DOI: 10.1007/S11307-019-01337-2  0.359
2019 Membreno R, Keinänen OM, Cook BE, Tully KM, Fung KC, Lewis JS, Zeglis BM. Towards the Optimization of Click-Mediated Pretargeted Radioimmunotherapy. Molecular Pharmaceutics. PMID 30912951 DOI: 10.1021/Acs.Molpharmaceut.9B00062  0.324
2019 Kramer GM, Yaqub M, Vargas HA, Schuit R, Windhorst AD, van den Eertwegh A, van der Veldt A, Bergman A, Burnazi E, Lewis JS, Chua SS, Staton K, Beattie BJ, Humm JL, Davis ID, et al. Assessment of simplified methods for quantification of F-FDHT uptake in patients with metastatic castration-resistant prostate cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 30850488 DOI: 10.2967/Jnumed.118.220111  0.335
2019 Cutler CS, Lewis JS, Anderson CJ. Utilization of metabolic, transport and receptor-mediated processes to deliver agents for cancer diagnosis. Advanced Drug Delivery Reviews. 37: 189-211. PMID 10837735 DOI: 10.1016/S0169-409X(98)00093-3  0.349
2019 Jhaveri K, Dunphy M, Wang R, Comen E, Fornier M, Moynahan M, Bromberg J, Ma W, Patil S, Taldone T, Rodina A, Sterlin V, Khoshi S, Lewis J, Norton L, et al. Abstract P6-20-03: Tumor epichaperome expression using 124I PU-H71 PET (PU-PET) as a biomarker of response for PU-H71 plus nab-paclitaxel in HER2 negative (HER2-) metastatic breast cancer (MBC) Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P6-20-03  0.374
2019 Lewis JS. Abstract I18: Retooling a blood-based biomarker into a theranostic agent Cancer Research. 79. DOI: 10.1158/1538-7445.Panca19-I18  0.419
2019 Crawford T, Moshnikova A, Roles S, Carter LM, Lewis JS, Engelman DM, Andreev OA, Reshetnyak YK. Abstract 1956: ICG pHLIP: A novel agent for fluorescence-guided surgery Cancer Research. 79: 1956-1956. DOI: 10.1158/1538-7445.Am2019-1956  0.399
2019 Tully K, Demoin D, Deri M, Hatcher J, Francesconi L, Lewis J. Evaluating HOPO chelators with therapeutic radioisotopes for theranostic applications in immunoPET imaging and radioimmunotherapy Nuclear Medicine and Biology. DOI: 10.1016/S0969-8051(19)30324-5  0.327
2019 Poty S, Knight JC, Donabedian P, Mandleywala K, Cornelissen B, Reiner T, Lewis JS. PET Imaging of DNA Damage Response following 225Ac-radioimmunotherapy in a Pancreatic Ductal Adenocarcinoma Mouse Model Journal of Medical Imaging and Radiation Sciences. 50: S4-S5. DOI: 10.1016/J.Jmir.2019.03.014  0.324
2019 Ulaner G, Sobol N, O'Donoghue J, Lyashchenko S, Lewis J, Landgren CO. Synthesis, preclinical analysis, and first-in-human phase I imaging of 89Zr-DFO-daratumumab for CD38 targeted imaging of myeloma Clinical Lymphoma Myeloma and Leukemia. 19: e19. DOI: 10.1016/J.Clml.2019.09.027  0.308
2018 Pereira PMR, Sharma SK, Carter LM, Edwards KJ, Pourat J, Ragupathi A, Janjigian YY, Durack JC, Lewis JS. Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy. Nature Communications. 9: 5137. PMID 30510281 DOI: 10.1038/S41467-018-07608-W  0.303
2018 Sanchez-Vega F, Hechtman JF, Castel P, Ku GY, Tuvy Y, Won H, Fong CJ, Bouvier N, Nanjangud GJ, Soong J, Vakiani E, Schattner M, Kelsen DP, Lefkowitz RA, Brown K, ... Lewis JS, et al. EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer. Cancer Discovery. PMID 30463996 DOI: 10.1158/2159-8290.Cd-18-0598  0.328
2018 Krebs S, Pandit-Taskar N, Reidy D, Beattie BJ, Lyashchenko SK, Lewis JS, Bodei L, Weber WA, O'Donoghue JA. Biodistribution and radiation dose estimates for Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors. European Journal of Nuclear Medicine and Molecular Imaging. PMID 30374529 DOI: 10.1007/S00259-018-4193-Y  0.382
2018 Senders ML, Hernot S, Carlucci G, van de Voort JC, Fay F, Calcagno C, Tang J, Alaarg A, Zhao Y, Ishino S, Palmisano A, Boeykens G, Meerwaldt AE, Sanchez-Gaytan BL, Baxter S, ... Lewis JS, et al. Nanobody-Facilitated Multiparametric PET/MRI Phenotyping of Atherosclerosis. Jacc. Cardiovascular Imaging. PMID 30343086 DOI: 10.1016/J.Jcmg.2018.07.027  0.328
2018 Henry KE, Dacek MM, Dilling TR, Caen JD, Fox IL, Evans MJ, Lewis JS. A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30228208 DOI: 10.1158/1078-0432.Ccr-18-1485  0.352
2018 Brand C, Sadique A, Houghton JL, Gangangari K, Ponte JF, Lewis JS, Pillarsetty NVK, Konner JA, Reiner T. Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate. Ejnmmi Research. 8: 87. PMID 30155674 DOI: 10.1186/S13550-018-0437-X  0.384
2018 Henry KE, Ulaner GA, Lewis JS. Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast Cancer. Pet Clinics. 13: 423-435. PMID 30100080 DOI: 10.1016/J.Cpet.2018.02.010  0.35
2018 McKnight BN, Kuda-Wedagedara ANW, Sevak KK, Abdel-Atti D, Wiesend WN, Ku A, Selvakumar D, Carlin SD, Lewis JS, Viola-Villegas NT. Imaging EGFR and HER3 through Zr-labeled MEHD7945A (Duligotuzumab). Scientific Reports. 8: 9043. PMID 29899472 DOI: 10.1038/S41598-018-27454-6  0.369
2018 Vargas HA, Kramer GM, Scott AM, Weickhardt A, Meier AA, Parada N, Beattie BJ, Humm JL, Staton KD, Zanzonico PB, Lyashchenko SK, Lewis JS, Yaqub M, Sosa RE, van den Eertwegh AJ, et al. Reproducibility and repeatability of semi-quantitativeF-fluorodihydrotestosterone (FDHT) uptake metrics in castration-resistant prostate cancer metastases: a prospective multi-center study. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29626121 DOI: 10.2967/Jnumed.117.206490  0.34
2018 Jannetti SA, Carlucci G, Carney B, Kossatz S, Shenker L, Carter LM, Salinas B, Brand C, Sadique A, Donabedian PL, Cunanan KM, Gönen M, Ponomarev V, Zeglis BM, Souweidane MM, Lewis JS, et al. PARP1-Targeted Radiotherapy in Mouse Models of Glioblastoma. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29572254 DOI: 10.2967/Jnumed.117.205054  0.339
2018 Escorcia FE, Steckler JM, Abdel-Atti D, Price EW, Carlin SD, Scholz WW, Lewis JS, Houghton JL. Tumor-Specific Zr-89 Immuno-PET Imaging in a Human Bladder Cancer Model. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. PMID 29508263 DOI: 10.1007/S11307-018-1177-Z  0.419
2018 Membreno R, Cook BE, Fung K, Lewis JS, Zeglis BM. Click-Mediated Pretargeted Radioimmunotherapy of Colorectal Carcinoma. Molecular Pharmaceutics. PMID 29502416 DOI: 10.1021/Acs.Molpharmaceut.8B00093  0.357
2018 Pereira PMR, Abma L, Henry KE, Lewis JS. Imaging of human epidermal growth factor receptors for patient selection and response monitoring - From PET imaging and beyond. Cancer Letters. 419: 139-151. PMID 29414302 DOI: 10.1016/J.Canlet.2018.01.052  0.359
2018 Carter LM, Poty S, Sharma SK, Lewis JS. Preclinical Optimization of Antibody-based Radiopharmaceuticals for Cancer Imaging and Radionuclide Therapy - Model, Vector, and Radionuclide Selection. Journal of Labelled Compounds & Radiopharmaceuticals. PMID 29412489 DOI: 10.1002/Jlcr.3612  0.31
2018 Dunphy MPS, Harding JJ, Venneti S, Zhang H, Burnazi EM, Bromberg J, Omuro AM, Hsieh JJ, Mellinghoff IK, Staton K, Pressl C, Beattie BJ, Zanzonico PB, Gerecitano JF, Kelsen DP, ... Lewis JS, et al. In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of 18F-(2S,4R )-4-Fluoroglutamine. Radiology. 162610. PMID 29388903 DOI: 10.1148/Radiol.2017162610  0.416
2018 Meyer JP, Tully KM, Jackson J, Dilling TR, Reiner T, Lewis JS. Bioorthogonal masking of circulating antibody-TCO groups using tetrazine-functionalized dextran polymers. Bioconjugate Chemistry. PMID 29378403 DOI: 10.1021/Acs.Bioconjchem.8B00028  0.403
2018 Postow MA, Harding JJ, Hellmann MD, Gordon MS, Tsai F, O' Donoghue JA, Lewis JS, Wu AM, Le W, Korn RL, Weber W, Wolchok JD, Pandit-Taskar N. Imaging of tumor infiltrating T cells with an anti-CD8 minibody (Mb) 89Zr-IAB22M2C, in advanced solid tumors. Journal of Clinical Oncology. 36: e24160-e24160. DOI: 10.1200/Jco.2018.36.15_Suppl.E24160  0.31
2018 Suzuki M, Xu H, Guo H, Nemieboka B, Wu Z, Lewis J, Cheung NV. Abstract A30: Novel T-cell engaging antibodies against L1CAM for neuroblastoma Cancer Research. 78. DOI: 10.1158/1538-7445.Pedca17-A30  0.325
2018 O'Reilly EA, Lohrmann C, O'Donoghue JA, Borazanci E, Estrella H, Teng R, Melink T, Dorr K, Kearns C, Peterson M, Ostrowski J, Gutheil J, Maffuid PW, Lewis JS, Weber W. Abstract CT140: Phase I dose escalation study of 177Lu-HuMab-5B1 (MVT-1075) in combination with MVT-5873 as radioimmunotherapy (RIT) in subjects with relapsed / refractory pancreatic cancer or other CA19-9+ malignancies Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Ct140  0.314
2018 Evans MJ, Truillet C, Ruggero D, Lewis JS, Aggarwal R, Behr SC. Abstract 3694: Measuring oncogene signaling with transferrin-based PET: From bench to bedside Cancer Research. 78: 3694-3694. DOI: 10.1158/1538-7445.Am2018-3694  0.363
2017 Heinzmann K, Carter LM, Lewis JS, Aboagye EO. Multiplexed imaging for diagnosis and therapy. Nature Biomedical Engineering. 1: 697-713. PMID 31015673 DOI: 10.1038/S41551-017-0131-8  0.348
2017 Ulaner GA, Lyashchenko SK, Riedl C, Ruan S, Zanzonico PB, Lake D, Jhaveri K, Zeglis B, Lewis JS, O'Donoghue JA. First-in-human HER2-targeted imaging using (89)Zr-pertuzumab PET/CT: Dosimetry and clinical application in patients with breast cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29146695 DOI: 10.2967/Jnumed.117.202010  0.377
2017 Fox JJ, Gavane SC, Blanc-Autran E, Nehmeh S, Gönen M, Beattie B, Vargas HA, Schöder H, Humm JL, Fine SW, Lewis JS, Solomon SB, Osborne JR, Veach D, Sawyers CL, et al. Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer. Jama Oncology. e173588. PMID 29121144 DOI: 10.1001/Jamaoncol.2017.3588  0.372
2017 Anderson CJ, Lewis JS. Current status and future challenges for molecular imaging. Philosophical Transactions. Series a, Mathematical, Physical, and Engineering Sciences. 375. PMID 29038378 DOI: 10.1098/Rsta.2017.0023  0.303
2017 Ulaner GA, Hyman DM, Lyashchenko SK, Lewis JS, Carrasquillo JA. 89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer. Clinical Nuclear Medicine. PMID 28872549 DOI: 10.1097/Rlu.0000000000001820  0.32
2017 Meyer JP, Kozlowski P, Jackson J, Cunanan KM, Adumeau P, Dilling TR, Zeglis BM, Lewis JS. Exploring Structural Parameters for Pretargeting Radioligand Optimization. Journal of Medicinal Chemistry. PMID 28857566 DOI: 10.1021/Acs.Jmedchem.7B01108  0.341
2017 Henry KE, Dilling TR, Abdel-Atti D, Edwards KJ, Evans MJ, Lewis JS. Non-invasive (89)Zr-Transferrin PET Shows Improved Tumor Targeting Compared to (18)F-FDG PET in MYC-overexpressing Human Triple Negative Breast Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 28848040 DOI: 10.2967/Jnumed.117.192286  0.42
2017 Tang J, Salloum D, Carney B, Brand C, Kossatz S, Sadique A, Lewis JS, Weber WA, Wendel HG, Reiner T. Targeted PET imaging strategy to differentiate malignant from inflamed lymph nodes in diffuse large B-cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America. PMID 28827325 DOI: 10.1073/Pnas.1705013114  0.38
2017 Cornelis FH, Durack J, Pandit-Taskar N, Ulaner GA, Lewis JS, Morris MJ, Solomon SB. Long Half-life (89)Zr Labeled Radiotracers Can Guide In Suite Percutaneous Molecular Imaging PET/CT-guided Biopsies Without Reinjection of Radiotracer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 28818992 DOI: 10.2967/Jnumed.117.194480  0.364
2017 Pandit-Taskar N, Zanzonico PB, Staton KD, Carrasquillo JA, Reidy-Lagunes D, Lyashchenko SK, Burnazi E, Zhang H, Lewis JS, Blasberg R, Larson SM, Weber WA, Modak S. Biodistribution and dosimetry of (18)F-Meta Fluorobenzyl Guanidine (MFBG): A first-in-human PET-CT imaging study of patients with neuroendocrine malignancies. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 28705916 DOI: 10.2967/Jnumed.117.193169  0.388
2017 O'Donoghue JA, Lewis JS, Pandit-Taskar N, Fleming SE, Schoder H, Larson SM, Beylergil V, Ruan S, Lyashchenko S, Zanzonico PB, Weber WA, Carrasquillo JA, Janjigian YY. Pharmacokinetics, biodistribution, and radiation dosimetry for (89)Zr-trastuzumab in patients with esophagogastric cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 28637800 DOI: 10.2967/Jnumed.117.194555  0.382
2017 Rao TD, Fernández-Tejada A, Axelrod A, Rosales N, Yan X, Thapi S, Wang A, Park KJ, Nemieboka B, Xiang J, Lewis JS, Olvera N, Levine DA, Danishefsky SJ, Spriggs D. Antibodies Against Specific MUC16 Glycosylation Sites Inhibit Ovarian Cancer Growth. Acs Chemical Biology. PMID 28617578 DOI: 10.1021/Acschembio.7B00305  0.302
2017 Henry KE, Ulaner GA, Lewis JS. Human Epidermal Growth Factor Receptor 2-Targeted PET/Single- Photon Emission Computed Tomography Imaging of Breast Cancer: Noninvasive Measurement of a Biomarker Integral to Tumor Treatment and Prognosis. Pet Clinics. 12: 269-288. PMID 28576166 DOI: 10.1016/J.Cpet.2017.02.001  0.391
2017 Sharma SK, Pourat J, Abdel-Atti D, Carlin SD, Piersigilli A, Bankovich AJ, Gardner EE, Hamdy O, Isse K, Bheddah S, Sandoval J, Cunanan KM, Johansen EB, Allaj V, Sisodiya V, ... Lewis JS, et al. Non-invasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer. Cancer Research. PMID 28487384 DOI: 10.1158/0008-5472.Can-17-0299  0.399
2017 Wyatt LC, Lewis JS, Andreev OA, Reshetnyak YK, Engelman DM. Applications of pHLIP Technology for Cancer Imaging and Therapy. Trends in Biotechnology. PMID 28438340 DOI: 10.1016/J.Tibtech.2017.03.014  0.379
2017 Di Gialleonardo V, Aldeborgh HN, Miloushev V, Folkers KM, Granlund K, Tap WD, Lewis JS, Weber WA, Keshari K. Multinuclear NMR and MRI reveal an early metabolic response to mTOR inhibition in sarcoma. Cancer Research. PMID 28386017 DOI: 10.1158/0008-5472.Can-16-3310  0.32
2017 Price EW, Carnazza KE, Carlin SD, Cho A, Edwards KJ, Sevak KK, Glaser JM, de Stanchina E, Janjigian YY, Lewis JS. (89)Zr-DFO-AMG102 Immuno-PET to Determine Local HGF Protein Levels in Tumors for Enhanced Patient Selection. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 28280216 DOI: 10.2967/Jnumed.116.187310  0.412
2017 Houghton JL, Abdel-Atti D, Scholz WW, Lewis JS. Preloading with unlabeled CA19.9 targeted human monoclonal antibody leads to improved PET imaging with 89Zr‑5B1. Molecular Pharmaceutics. PMID 28191976 DOI: 10.1021/Acs.Molpharmaceut.6B01130  0.392
2017 Houghton JL, Membreno R, Abdel-Atti D, Cunanan KM, Carlin S, Scholz WW, Zanzonico PB, Lewis JS, Zeglis BM. Establishment of the In Vivo Efficacy of Pretargeted Radioimmunotherapy Utilizing Inverse Electron Demand Diels-Alder Click Chemistry. Molecular Cancer Therapeutics. 16: 124-133. PMID 28062708 DOI: 10.1158/1535-7163.Mct-16-0503  0.396
2017 Houghton JL, Lanning R, Abdel-atti D, Jun T, Kearns CM, Schlosser M, Scholz W, Lewis JS, Maffuid PW. Abstract 5204: Preclinical development of MVT-1075 as radioimmunotherapy for pancreatic cancer and other CA19-9 positive malignancies Cancer Research. 77: 5204-5204. DOI: 10.1158/1538-7445.Am2017-5204  0.363
2017 Kramer K, Kushner B, Modak S, Pandit-Taskar N, Tomlinson U, Donzelli M, Wolden S, Zanzonico P, Humm J, Haque S, Souweidane M, Greenfield J, Basu E, Roberts S, Carrasquillo J, ... Lewis J, et al. SCDT-38. SAFETY AND EFFICACY OF INTRAVENTRICULAR 131I-LABELED MONOCLONAL ANTIBODY 8H9 TARGETING THE SURFACE GLYCOPROTEIN B7-H3 IN PATIENTS WITH CNS/LM DISEASE Neuro-Oncology. 19: vi272-vi272. DOI: 10.1093/Neuonc/Nox168.1119  0.316
2016 Adumeau P, Carnazza KE, Brand C, Carlin SD, Reiner T, Agnew BJ, Lewis JS, Zeglis BM. A Pretargeted Approach for the Multimodal PET/NIRF Imaging of Colorectal Cancer. Theranostics. 6: 2267-2277. PMID 27924162 DOI: 10.7150/Thno.16744  0.446
2016 Thorek DL, Watson PA, Lee SG, Ku AT, Bournazos S, Braun K, Kim K, Sjöström K, Doran MG, Lamminmäki U, Santos E, Veach D, Turkekul M, Casey E, Lewis JS, et al. Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis. Science Translational Medicine. 8: 367ra167. PMID 27903863 DOI: 10.1126/Scitranslmed.Aaf2335  0.337
2016 Ulaner GA, Goldman D, Corben A, Lyashchenko S, Gonen M, Lewis J, Dickler M. A prospective clinical trial of 18F-Fluciclovine PET/CT neoadjuvant therapy response in invasive ductal and invasive lobular breast cancers. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 27856630 DOI: 10.2967/Jnumed.116.183335  0.356
2016 Meyer JP, Adumeau P, Lewis JS, Zeglis BM. Click Chemistry and Radiochemistry: The First Ten Years. Bioconjugate Chemistry. PMID 27787983 DOI: 10.1021/Acs.Bioconjchem.6B00561  0.32
2016 O'Connor JP, Aboagye EO, Adams JE, Aerts HJ, Barrington SF, Beer AJ, Boellaard R, Bohndiek SE, Brady M, Brown G, Buckley DL, Chenevert TL, Clarke LP, Collette S, Cook GJ, ... Lewis JS, et al. Imaging biomarker roadmap for cancer studies. Nature Reviews. Clinical Oncology. PMID 27725679 DOI: 10.1038/Nrclinonc.2016.162  0.305
2016 Pandit-Taskar N, O'Donoghue JA, Ruan S, Lyashchenko S, Carrasquillo JA, Heller G, Martinez DF, Cheal SM, Lewis JS, Fleisher M, Keppler JS, Reiter RE, Wu AM, Weber WA, Scher HI, et al. First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 27516450 DOI: 10.2967/Jnumed.116.176206  0.318
2016 Demoin DW, Shindo M, Zhang H, Edwards KJ, Serganova I, Pillarsetty NV, Lewis JS, Blasberg RG. Synthesis and evaluation of an (18)F-labeled pyrimidine-pyridine amine for targeting CXCR4 receptors in gliomas. Nuclear Medicine and Biology. 43: 606-611. PMID 27485481 DOI: 10.1016/J.Nucmedbio.2016.05.005  0.301
2016 Demoin DW, Wyatt LC, Edwards KJ, Abdel-Atti D, Sarparanta MP, Pourat J, Longo VA, Carlin SD, Engelman DM, Andreev OA, Reshetnyak YK, Viola-Villegas N, Lewis JS. PET Imaging of Extracellular pH in Tumors with (64)Cu- and (18)F-labeled pHLIP peptides: A Structure-Activity Optimization Study. Bioconjugate Chemistry. PMID 27396694 DOI: 10.1021/Acs.Bioconjchem.6B00306  0.404
2016 Meyer JP, Edwards KJ, Kozlowski P, Backer MV, Backer JM, Lewis JS. Selective imaging of VEGFR-1 and VEGFR-2 receptors using 89Zr-labeled single-chain VEGF mutants. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 27390161 DOI: 10.2967/Jnumed.116.173237  0.319
2016 Cook BE, Adumeau P, Membreno R, Carnazza KE, Brand C, Reiner T, Agnew BJ, Lewis JS, Zeglis BM. Pretargeted PET Imaging Using a Site-Specifically Labeled Immunoconjugate. Bioconjugate Chemistry. PMID 27356886 DOI: 10.1021/Acs.Bioconjchem.6B00235  0.442
2016 Pérez-Medina C, Abdel-Atti D, Tang J, Zhao Y, Fayad ZA, Lewis JS, Mulder WJ, Reiner T. Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy. Nature Communications. 7: 11838. PMID 27319780 DOI: 10.1038/Ncomms11838  0.375
2016 Pérez-Medina C, Binderup T, Lobatto ME, Tang J, Calcagno C, Giesen L, Wessel CH, Witjes J, Ishino S, Baxter S, Zhao Y, Ramachandran S, Eldib M, Sánchez-Gaytán BL, Robson PM, ... Lewis JS, et al. In Vivo PET Imaging of HDL in Multiple Atherosclerosis Models. Jacc. Cardiovascular Imaging. PMID 27236528 DOI: 10.1016/J.Jcmg.2016.01.020  0.361
2016 Ulaner GA, Hyman D, Ross D, Corben A, Chandarlapaty S, Goldfarb S, McArthur H, Erinjeri J, Solomon S, Kolb H, Lyashchenko S, Lewis J, Carrasquillo J. Detection of HER2-positive metastases in patients with HER2-negative primary breast cancer using the 89Zr-DFO-trastuzumab PET/CT. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 27151988 DOI: 10.2967/Jnumed.115.172031  0.336
2016 Sharma SK, Nemieboka B, Sala E, Lewis JS, Zeglis BM. Molecular Imaging of Ovarian Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 27127223 DOI: 10.2967/Jnumed.115.172023  0.37
2016 Ulaner GA, Goldman D, Gonen M, Pham H, Castillo R, Lyashchenko S, Lewis J, Dang C. Initial results of a prospective clinical trial of 18F-Fluciclovine PET/CT in newly diagnosed invasive ductal and invasive lobular breast cancers. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 26940766 DOI: 10.2967/Jnumed.115.170456  0.35
2016 Sharma SK, Sevak KK, Monette S, Carlin SD, Knight JC, Wuest FR, Sala E, Zeglis BM, Lewis JS. Preclinical 89Zr-immunoPET of High Grade Serous Ovarian Cancer and Lymph Node Metastasis. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 26837339 DOI: 10.2967/Jnumed.115.167072  0.315
2016 Taldone T, Zatorska D, Ochiana SO, Smith-Jones P, Koziorowski J, Dunphy MP, Zanzonico P, Bolaender A, Lewis JS, Larson SM, Chiosis G, Pillarsetty NV. Radiosynthesis of the iodine-124 labeled Hsp90 inhibitor PU-H71. Journal of Labelled Compounds & Radiopharmaceuticals. PMID 26806023 DOI: 10.1002/Jlcr.3369  0.322
2016 Doran MG, Carnazza KE, Steckler JM, Spratt DE, Truillet C, Wongvipat J, Sawyers CL, Lewis JS, Evans MJ. Applying 89Zr-transferrin to study the pharmacology of inhibitors to BET bromodomain containing proteins. Molecular Pharmaceutics. PMID 26725682 DOI: 10.1021/Acs.Molpharmaceut.5B00882  0.365
2016 Morris MJ, Martinez DF, Durack JC, Slovin SF, Danila DC, O' Donoghue JA, Parada NA, Lyashchenko SK, Carrasquillo JA, Ruan S, Lewis JS, Keppler J, Wu AM, Reuter VE, Weber W, et al. A phase I/IIa trial of prostate specific membrane antigen (PSMA) positron emission tomography (PET) imaging with 89Zr-Df-IAB2M in metastatic prostate cancer (PCa). Journal of Clinical Oncology. 34: 287-287. DOI: 10.1200/Jco.2016.34.2_Suppl.287  0.353
2016 Nemieboka BE, Thapi D, Bitton A, Lewis JS. Abstract B25: Preclinical evaluation of radiolabeled MUC16 antibodies for PET imaging of epithelial ovarian carcinoma. Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Ovca15-B25  0.357
2016 Price EW, Glaser JM, Edwards KJ, Lewis JS. Abstract LB-182: Optimized antibody modification and radiolabeling conditions for zirconium-89 immuno-PET Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-182  0.376
2016 Demoin DW, Edwards KJ, Wyatt LC, Sarparanta M, Pourat J, Andreev OA, Reshetnyak YK, Viola-Villegas N, Lewis JS. Abstract 4205: Targeting a variety of cancers with NOTA-derivatized pH (low) insertion peptide (pHLIP) complexes with64Cu and18F: What cancers are targetable Cancer Research. 76: 4205-4205. DOI: 10.1158/1538-7445.Am2016-4205  0.418
2016 Houghton J, Membreno R, Abdel-Atti D, Scholz WW, Zeglis BM, Lewis JS. Abstract 3051: Improving the efficacy of pretargeted radioimmunotherapy in preclinical murine models by utilizing bioorthogonal click chemistry Cancer Research. 76: 3051-3051. DOI: 10.1158/1538-7445.Am2016-3051  0.371
2015 Houghton JL, Zeglis BM, Abdel-Atti D, Aggeler R, Sawada R, Agnew BJ, Scholz WW, Lewis JS. Site-specifically labeled CA19.9-targeted immunoconjugates for the PET, NIRF, and multimodal PET/NIRF imaging of pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America. PMID 26668398 DOI: 10.1073/Pnas.1506542112  0.438
2015 Deri M, Ponnala S, Kozlowski P, Burton-Pye BP, Cicek H, Hu C, Lewis JS, Francesconi LC. p-SCN-BN-HOPO: A Superior Bifunctional Chelator for (89)Zr ImmunoPET. Bioconjugate Chemistry. PMID 26550847 DOI: 10.1021/Acs.Bioconjchem.5B00572  0.373
2015 Meyer JP, Houghton JL, Kozlowski P, Abdel-Atti D, Reiner T, Pillarsetty NV, Scholz WW, Zeglis BM, Lewis JS. (18)F-Based Pretargeted PET Imaging Based on Bioorthogonal Diels-Alder Click Chemistry. Bioconjugate Chemistry. PMID 26479967 DOI: 10.1021/Acs.Bioconjchem.5B00504  0.387
2015 Houghton JL, Zeglis BM, Abdel-Atti D, Sawada R, Scholz WW, Lewis JS. Pretargeted immunoPET of pancreatic cancer: overcoming circulating antigen and antibody internalization to reduce radiation doses. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 26471693 DOI: 10.2967/Jnumed.115.163824  0.364
2015 Zeglis BM, Brand C, Abdel-Atti D, Carnazza KE, Cook BE, Carlin S, Reiner T, Lewis JS. Optimization of a Pretargeted Strategy for the PET Imaging of Colorectal Carcinoma via the Modulation of Radioligand Pharmacokinetics. Molecular Pharmaceutics. PMID 26287993 DOI: 10.1021/Acs.Molpharmaceut.5B00294  0.48
2015 Pandit-Taskar N, O'Donoghue JA, Durack JC, Lyashchenko SK, Cheal SM, Beylergil V, Lefkowitz RA, Carrasquillo JA, Martinez DF, Fung AM, Solomon SB, Gonen M, Heller G, Loda M, Nanus DM, ... Lewis JS, et al. A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26175541 DOI: 10.1158/1078-0432.Ccr-15-0552  0.37
2015 Perez-Medina C, Tang J, Abdel-Atti D, Hogstad B, Merad M, Fisher EA, Fayad ZA, Lewis JS, Mulder WJ, Reiner T. PET Imaging of Tumor-Associated Macrophages with 89Zr-labeled HDL Nanoparticles. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 26112022 DOI: 10.2967/Jnumed.115.158956  0.415
2015 Dimastromatteo J, Houghton JL, Lewis JS, Kelly KA. Challenges of Pancreatic Cancer. Cancer Journal (Sudbury, Mass.). 21: 188-93. PMID 26049698 DOI: 10.1097/Ppo.0000000000000109  0.357
2015 Lazari M, Lyashchenko SK, Burnazi EM, Lewis JS, Michael van Dam R, Murphy JM. Fully-automated synthesis of 16β-(18)F-fluoro-5α-dihydrotestosterone (FDHT) on the ELIXYS radiosynthesizer. Applied Radiation and Isotopes : Including Data, Instrumentation and Methods For Use in Agriculture, Industry and Medicine. 103: 9-14. PMID 26046518 DOI: 10.1016/J.Apradiso.2015.05.010  0.35
2015 Bosch A, Li Z, Bergamaschi A, Ellis H, Toska E, Prat A, Tao JJ, Spratt DE, Viola-Villegas NT, Castel P, Minuesa G, Morse N, Rodón J, Ibrahim Y, Cortes J, ... Lewis JS, et al. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Science Translational Medicine. 7: 283ra51. PMID 25877889 DOI: 10.1126/Scitranslmed.Aaa4442  0.308
2015 Reiner T, Lewis JS, Zeglis BM. Harnessing the bioorthogonal inverse electron demand Diels-Alder cycloaddition for pretargeted PET imaging. Journal of Visualized Experiments : Jove. e52335. PMID 25742199 DOI: 10.3791/52335  0.427
2015 Zeglis BM, Lewis JS. The bioconjugation and radiosynthesis of 89Zr-DFO-labeled antibodies. Journal of Visualized Experiments : Jove. PMID 25741890 DOI: 10.3791/52521  0.39
2015 Lapi SE, Lewis JS, Dehdashti F. Evaluation of hypoxia with copper-labeled diacetyl-bis(N-methylthiosemicarbazone). Seminars in Nuclear Medicine. 45: 177-85. PMID 25704389 DOI: 10.1053/J.Semnuclmed.2014.10.003  0.363
2015 Venneti S, Dunphy MP, Zhang H, Pitter KL, Zanzonico P, Campos C, Carlin SD, La Rocca G, Lyashchenko S, Ploessl K, Rohle D, Omuro AM, Cross JR, Brennan CW, Weber WA, ... Lewis JS, et al. Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo. Science Translational Medicine. 7: 274ra17. PMID 25673762 DOI: 10.1126/Scitranslmed.Aaa1009  0.394
2015 Morris MJ, Solomon SB, Durack JC, O' Donoghue JA, Lyashchenko SK, Shutian R, Carrasquillo JA, Lewis JS, Martinez DF, Parada NA, Keppler J, Wu A, Reuter VE, Weber W, Scher HI, et al. Pathologic correlation of 89Zr-Df-IAB2M antiprostate-specific membrane antigen (PSMA) minibody in patients with metastatic prostate cancer. Journal of Clinical Oncology. 33: 220-220. DOI: 10.1200/Jco.2015.33.7_Suppl.220  0.391
2015 Gerecitano JF, Modi S, Rampal R, Drilon AE, Fury MG, Gounder MM, Harding JJ, Hyman DM, Varghese AM, Voss MH, France FO, Taldone T, Gomes DaGama E, Uddin M, Chiosis G, ... Lewis JS, et al. Phase I trial of the HSP-90 inhibitor PU-H71. Journal of Clinical Oncology. 33: 2537-2537. DOI: 10.1200/Jco.2015.33.15_Suppl.2537  0.318
2015 Dunphy M, Harding JJ, Lewis JS, Mellinghoff IK, Omuro AMP, Hsieh J, Zhang H, Zanzonico P, Venneti S, Carlin S, Younes A, Gerecitano JF, Lyashchenko SK, Harris L, Lashley A, et al. Phenotypic correlation of tumor uptake of exogenous glutamine radiotracer versus tumor mutational status. Journal of Clinical Oncology. 33: 11014-11014. DOI: 10.1200/Jco.2015.33.15_Suppl.11014  0.391
2015 Lewis JS. Abstract IA16: New methods of PET imaging pancreas cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Panca2014-Ia16  0.419
2015 Houghton JL, Abdel-Atti DA, Sawada R, Scholz WW, Lewis JS. Abstract B25: Development of 5B1, an anti-CA19.9 monoclonal antibody, as a near-infrared fluorescent probe for intraoperative imaging of pancreatic cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Panca2014-B25  0.379
2015 Taldone T, Pillarsetty N, Dunphy MP, Gerecitano JF, Caldas-Lopes E, Beattie B, Peter RI, Kang Y, Rodina A, Yan P, Gomes EMD, Bolaender A, Pressl C, Punzalan B, Ku A, ... Lewis JS, et al. Abstract 5444: Development of a noninvasive assay to determine drug concentration in tumor during hsp90 inhibitor therapy Cancer Research. 75: 5444-5444. DOI: 10.1158/1538-7445.Am2015-5444  0.4
2015 Thorek D, Braun K, Lewis J, Scardino P, Lilja H, Larson S, Ulmert D. MP37-10 11B6 MAB: APPLICATIONS FOR PROSTATE CANCER STAGING, INTRA-OPERATIVE GUIDANCE AND EVALUATION OF TREATMENT BY IN VIVO IMAGING OF HK2 Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.1273  0.332
2014 Contag C, Pogue B, Lewis J. MO-C-BRE-01: The WMIS-AAPM Joint Symposium: Advances in Molecular Imaging. Medical Physics. 41: 412. PMID 28036785 DOI: 10.1118/1.4889121  0.356
2014 Doran MG, Watson PA, Cheal SM, Spratt DE, Wongvipat J, Steckler JM, Carrasquillo JA, Evans MJ, Lewis JS. Annotating STEAP1 regulation in prostate cancer with 89Zr immuno-PET. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 55: 2045-9. PMID 25453051 DOI: 10.2967/Jnumed.114.145185  0.303
2014 Zeglis BM, Davis CB, Abdel-Atti D, Carlin SD, Chen A, Aggeler R, Agnew BJ, Lewis JS. Chemoenzymatic strategy for the synthesis of site-specifically labeled immunoconjugates for multimodal PET and optical imaging. Bioconjugate Chemistry. 25: 2123-8. PMID 25418333 DOI: 10.1021/Bc500499H  0.399
2014 Daumar P, Zeglis BM, Ramos N, Divilov V, Sevak KK, Pillarsetty N, Lewis JS. Synthesis and evaluation of (18)F-labeled ATP competitive inhibitors of topoisomerase II as probes for imaging topoisomerase II expression. European Journal of Medicinal Chemistry. 86: 769-81. PMID 25240701 DOI: 10.1016/J.Ejmech.2014.09.019  0.378
2014 Pandit-Taskar N, O'Donoghue JA, Beylergil V, Lyashchenko S, Ruan S, Solomon SB, Durack JC, Carrasquillo JA, Lefkowitz RA, Gonen M, Lewis JS, Holland JP, Cheal SM, Reuter VE, Osborne JR, et al. ⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. 41: 2093-105. PMID 25143071 DOI: 10.1007/S00259-014-2830-7  0.379
2014 Pérez-Medina C, Abdel-Atti D, Zhang Y, Longo VA, Irwin CP, Binderup T, Ruiz-Cabello J, Fayad ZA, Lewis JS, Mulder WJ, Reiner T. A modular labeling strategy for in vivo PET and near-infrared fluorescence imaging of nanoparticle tumor targeting. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 55: 1706-11. PMID 25060196 DOI: 10.2967/Jnumed.114.141861  0.362
2014 Adochite RC, Moshnikova A, Carlin SD, Guerrieri RA, Andreev OA, Lewis JS, Reshetnyak YK. Targeting breast tumors with pH (low) insertion peptides. Molecular Pharmaceutics. 11: 2896-905. PMID 25004202 DOI: 10.1021/Mp5002526  0.375
2014 Brand C, Abdel-Atti D, Zhang Y, Carlin S, Clardy SM, Keliher EJ, Weber WA, Lewis JS, Reiner T. In vivo imaging of GLP-1R with a targeted bimodal PET/fluorescence imaging agent. Bioconjugate Chemistry. 25: 1323-30. PMID 24856928 DOI: 10.1021/Bc500178D  0.393
2014 Deri MA, Ponnala S, Zeglis BM, Pohl G, Dannenberg JJ, Lewis JS, Francesconi LC. Alternative chelator for ⁸⁹Zr radiopharmaceuticals: radiolabeling and evaluation of 3,4,3-(LI-1,2-HOPO). Journal of Medicinal Chemistry. 57: 4849-60. PMID 24814511 DOI: 10.1021/Jm500389B  0.375
2014 Viola-Villegas NT, Carlin SD, Ackerstaff E, Sevak KK, Divilov V, Serganova I, Kruchevsky N, Anderson M, Blasberg RG, Andreev OA, Engelman DM, Koutcher JA, Reshetnyak YK, Lewis JS. Understanding the pharmacological properties of a metabolic PET tracer in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 111: 7254-9. PMID 24785505 DOI: 10.1073/Pnas.1405240111  0.397
2014 Viola-Villegas NT, Sevak KK, Carlin SD, Doran MG, Evans HW, Bartlett DW, Wu AM, Lewis JS. Noninvasive Imaging of PSMA in prostate tumors with (89)Zr-Labeled huJ591 engineered antibody fragments: the faster alternatives. Molecular Pharmaceutics. 11: 3965-73. PMID 24779727 DOI: 10.1021/Mp500164R  0.412
2014 Cheal SM, Punzalan B, Doran MG, Evans MJ, Osborne JR, Lewis JS, Zanzonico P, Larson SM. Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging. 41: 985-94. PMID 24604591 DOI: 10.1007/S00259-013-2679-1  0.355
2014 Zhang H, Huang R, Cheung NK, Guo H, Zanzonico PB, Thaler HT, Lewis JS, Blasberg RG. Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2182-91. PMID 24573553 DOI: 10.1158/1078-0432.Ccr-13-1153  0.354
2014 Zeglis BM, Houghton JL, Evans MJ, Viola-Villegas N, Lewis JS. Underscoring the influence of inorganic chemistry on nuclear imaging with radiometals. Inorganic Chemistry. 53: 1880-99. PMID 24313747 DOI: 10.1021/Ic401607Z  0.337
2014 Zhang H, Huang R, Pillarsetty N, Thorek DL, Vaidyanathan G, Serganova I, Blasberg RG, Lewis JS. Synthesis and evaluation of 18F-labeled benzylguanidine analogs for targeting the human norepinephrine transporter. European Journal of Nuclear Medicine and Molecular Imaging. 41: 322-32. PMID 24173571 DOI: 10.1007/S00259-013-2558-9  0.372
2014 Price EW, Zeglis BM, Lewis JS, Adam MJ, Orvig C. H6phospa-trastuzumab: bifunctional methylenephosphonate-based chelator with 89Zr, 111In and 177Lu. Dalton Transactions (Cambridge, England : 2003). 43: 119-31. PMID 24104523 DOI: 10.1039/C3Dt51940F  0.362
2014 Morris MJ, Pandit-Taskar N, Tagawa ST, Nanus DM, Solomon SB, Carrasquillo JA, Reuter VE, Lewis JS, Beylergil V, O' Donoghue JA, Lyashchenko SK, Martinez DF, Curtis KR, Durack JC, Cheal SM, et al. Tumor-directed PET imaging of bone metastases in metastatic castration-resistant prostate cancer (mCRPC) using Zr-89 labeled anti-prostate specific membrane antigen (PSMA) antibody J591. Journal of Clinical Oncology. 32: 25-25. DOI: 10.1200/Jco.2014.32.4_Suppl.25  0.39
2014 Olafsen T, Bartlett D, Ho D, Zhang G, Torgov M, Keppler J, Behrenbruch C, Wu A, Pandit-Taskar N, Morris MJ, Lewis JS, Lyashchenko SK, Gudas JM. Minibody imaging of prostate-specific membrane antigen (PSMA): From concept to clinic. Journal of Clinical Oncology. 32: e16057-e16057. DOI: 10.1200/Jco.2014.32.15_Suppl.E16057  0.407
2014 Venneti S, Dunphy M, Zhang H, Pitter K, Campos C, Carlin S, Lyashchenko S, Ploessl C, Rohle D, Omuro A, Cross J, Brennan C, Weber W, Holland E, Mellinghoff I, ... ... Lewis J, et al. TM-15 * GLUTAMINE BASED PET IMAGING FACILITATES ENHANCED METABOLIC DETECTION OF GLIOMAS IN VIVO Neuro-Oncology. 16: v216-v216. DOI: 10.1093/Neuonc/Nou278.14  0.381
2014 Sharma SK, Zeglis B, Sevak K, Lewis J, Wuest F. 89Zr immuno-PET of epithelial ovarian cancer Nuclear Medicine and Biology. 41: 638-639. DOI: 10.1016/J.Nucmedbio.2014.05.114  0.326
2013 Pandit-Taskar N, Carrasquillo JA, O' Donoghue JA, Humm J, Lyashchenko SK, Haupt EC, Bander NH, Tagawa ST, Holland JP, Smith-Jones PM, Lewis JS, Solomon SB, Scher HI, Larson SM. Phase I trial of zirconium 89 (Zr89) radiolabeled J591 in metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 31. PMID 28136972 DOI: 10.1200/Jco.2013.31.6_Suppl.31  0.34
2013 Emmetiere F, Irwin C, Viola-Villegas NT, Longo V, Cheal SM, Zanzonico P, Pillarsetty N, Weber WA, Lewis JS, Reiner T. (18)F-labeled-bioorthogonal liposomes for in vivo targeting. Bioconjugate Chemistry. 24: 1784-9. PMID 24180480 DOI: 10.1021/Bc400322H  0.388
2013 Gemignani ML, Patil S, Seshan VE, Sampson M, Humm JL, Lewis JS, Brogi E, Larson SM, Morrow M, Pandit-Taskar N. Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 54: 1697-702. PMID 23970364 DOI: 10.2967/Jnumed.112.113373  0.309
2013 Price EW, Zeglis BM, Cawthray JF, Ramogida CF, Ramos N, Lewis JS, Adam MJ, Orvig C. H(4)octapa-trastuzumab: versatile acyclic chelate system for 111In and 177Lu imaging and therapy. Journal of the American Chemical Society. 135: 12707-21. PMID 23901833 DOI: 10.1021/Ja4049493  0.415
2013 Yoshii Y, Furukawa T, Oyama N, Hasegawa Y, Kiyono Y, Nishii R, Waki A, Tsuji AB, Sogawa C, Wakizaka H, Fukumura T, Yoshii H, Fujibayashi Y, Lewis JS, Saga T. Fatty acid synthase is a key target in multiple essential tumor functions of prostate cancer: uptake of radiolabeled acetate as a predictor of the targeted therapy outcome. Plos One. 8: e64570. PMID 23741342 DOI: 10.1371/Journal.Pone.0064570  0.38
2013 Zeglis BM, Sevak KK, Reiner T, Mohindra P, Carlin SD, Zanzonico P, Weissleder R, Lewis JS. A pretargeted PET imaging strategy based on bioorthogonal Diels-Alder click chemistry. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 54: 1389-96. PMID 23708196 DOI: 10.2967/Jnumed.112.115840  0.39
2013 Zeglis BM, Davis CB, Aggeler R, Kang HC, Chen A, Agnew BJ, Lewis JS. Enzyme-mediated methodology for the site-specific radiolabeling of antibodies based on catalyst-free click chemistry. Bioconjugate Chemistry. 24: 1057-67. PMID 23688208 DOI: 10.1021/Bc400122C  0.318
2013 Zeng D, Zeglis BM, Lewis JS, Anderson CJ. The growing impact of bioorthogonal click chemistry on the development of radiopharmaceuticals. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 54: 829-32. PMID 23616581 DOI: 10.2967/Jnumed.112.115550  0.352
2013 Janjigian YY, Viola-Villegas N, Holland JP, Divilov V, Carlin SD, Gomes-DaGama EM, Chiosis G, Carbonetti G, de Stanchina E, Lewis JS. Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 54: 936-43. PMID 23578997 DOI: 10.2967/Jnumed.112.110239  0.324
2013 Evans MJ, Holland JP, Rice SL, Doran MG, Cheal SM, Campos C, Carlin SD, Mellinghoff IK, Sawyers CL, Lewis JS. Imaging tumor burden in the brain with 89Zr-transferrin. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 54: 90-5. PMID 23236019 DOI: 10.2967/Jnumed.112.109777  0.313
2013 Abou DS, Thorek DL, Ramos NN, Pinkse MW, Wolterbeek HT, Carlin SD, Beattie BJ, Lewis JS. (89)Zr-labeled paramagnetic octreotide-liposomes for PET-MR imaging of cancer. Pharmaceutical Research. 30: 878-88. PMID 23224977 DOI: 10.1007/S11095-012-0929-8  0.414
2013 Deri MA, Zeglis BM, Francesconi LC, Lewis JS. PET imaging with ⁸⁹Zr: from radiochemistry to the clinic. Nuclear Medicine and Biology. 40: 3-14. PMID 22998840 DOI: 10.1016/J.Nucmedbio.2012.08.004  0.37
2013 Slovin SF, Wang X, Hullings M, Arauz G, Bartido S, Lewis JS, Schöder H, Zanzonico P, Scher HI, Riviere I. Chimeric antigen receptor (CAR+) modified T cells targeting prostate specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC). Journal of Clinical Oncology. 31: 72-72. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps3115  0.319
2013 Gerecitano JF, Modi S, Gajria D, Taldone T, Alpaugh M, Gomes DaGama E, Uddin M, Chiosis G, Lewis JS, Larson SM, Pillarsetty NVK, Jhaveri KL, Krichevsky B, Chen MH, Dixit P, et al. Using 124I-PU-H71 PET imaging to predict intratumoral concentration in patients on a phase I trial of PU-H71. Journal of Clinical Oncology. 31: 11076-11076. DOI: 10.1200/Jco.2013.31.15_Suppl.11076  0.34
2013 Wagar M, Mannarino E, Williams C, Hacker F, Berbeco R, Lewis J. SU-E-J-141: A Patient Specific Anthropomorphic Breathing Phantom for Clinically Realistic Imaging and Dosimetry Studies Medical Physics. 40: 183-183. DOI: 10.1118/1.4814353  0.351
2013 Zeglis BM, Holland JP, Lebedev AY, Cantorias MV, Lewis JS. Radiopharmaceuticals for imaging in oncology with special emphasis on positron-emitting agents Nuclear Oncology: Pathophysiology and Clinical Applications. 35-78. DOI: 10.1007/978-0-387-48894-3_3  0.309
2012 Bailey GA, Price EW, Zeglis BM, Ferreira CL, Boros E, Lacasse MJ, Patrick BO, Lewis JS, Adam MJ, Orvig C. H(2)azapa: a versatile acyclic multifunctional chelator for (67)Ga, (64)Cu, (111)In, and (177)Lu. Inorganic Chemistry. 51: 12575-89. PMID 23106422 DOI: 10.1021/Ic302225Z  0.331
2012 Holland JP, Evans MJ, Rice SL, Wongvipat J, Sawyers CL, Lewis JS. Annotating MYC status with 89Zr-transferrin imaging. Nature Medicine. 18: 1586-91. PMID 23001181 DOI: 10.1038/Nm.2935  0.362
2012 Daumar P, Wanger-Baumann CA, Pillarsetty N, Fabrizio L, Carlin SD, Andreev OA, Reshetnyak YK, Lewis JS. Efficient (18)F-labeling of large 37-amino-acid pHLIP peptide analogues and their biological evaluation. Bioconjugate Chemistry. 23: 1557-66. PMID 22784215 DOI: 10.1021/Bc3000222  0.339
2012 Ulmert D, Evans MJ, Holland JP, Rice SL, Wongvipat J, Pettersson K, Abrahamsson PA, Scardino PT, Larson SM, Lilja H, Lewis JS, Sawyers CL. Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen. Cancer Discovery. 2: 320-7. PMID 22576209 DOI: 10.1158/2159-8290.Cd-11-0316  0.311
2012 Dunphy MP, Zanzonico P, Veach D, Somwar R, Pillarsetty N, Lewis J, Larson S. Dosimetry of 18F-labeled tyrosine kinase inhibitor SKI-249380, a dasatinib-tracer for PET imaging. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 14: 25-31. PMID 21161687 DOI: 10.1007/S11307-010-0462-2  0.386
2012 Modak S, Carrasquillo JA, La Quaglia MP, Zanzonico P, Pandit-Taskar N, Lewis JS, Cheung NV. Intraperitoneal radioimmunotherapy (RIT) for desmoplastic small round cell tumor (DSRCT). Journal of Clinical Oncology. 30: TPS9595-TPS9595. DOI: 10.1200/Jco.2012.30.15_Suppl.Tps9595  0.37
2012 Larson SM, Fox J, Morris M, Evans M, Lewis J, Humm J, Sawyers CL, Scher HI. Abstract IA22: Molecular Imaging of androgen receptor signalling in CRPC Cancer Research. 72: IA22-IA22. DOI: 10.1158/1538-7445.Prca2012-Ia22  0.402
2012 Rodina A, Moulick K, Ahn J, Zong H, Cerchietti L, DaGama EG, Caldas-Lopes E, Beebe K, Perna F, Hatzi K, Vu L, Zhao X, Zatorska D, Taldone T, Smith-Jones P, ... Lewis J, et al. Abstract 3029: Biochemical evidence towards the existence of an oncogenic Hsp90 complex Cancer Research. 72: 3029-3029. DOI: 10.1158/1538-7445.Am2012-3029  0.303
2012 Gomes-DaGama EM, Moulick K, Ahn JH, Zong H, Rodina A, Cerchietti L, Lopes-Vazquez MEC, Beebe K, Perna F, Katerina C, Vu LP, Zhao X, Zatorska D, Taldone T, Smith-Jones P, ... Lewis JS, et al. Abstract 1263: Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90 Cancer Research. 72: 1263-1263. DOI: 10.1158/1538-7445.Am2012-1263  0.327
2011 Keliher EJ, Yoo J, Nahrendorf M, Lewis JS, Marinelli B, Newton A, Pittet MJ, Weissleder R. 89Zr-labeled dextran nanoparticles allow in vivo macrophage imaging. Bioconjugate Chemistry. 22: 2383-9. PMID 22035047 DOI: 10.1021/Bc200405D  0.361
2011 Moulick K, Ahn JH, Zong H, Rodina A, Cerchietti L, Gomes DaGama EM, Caldas-Lopes E, Beebe K, Perna F, Hatzi K, Vu LP, Zhao X, Zatorska D, Taldone T, Smith-Jones P, ... ... Lewis JS, et al. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nature Chemical Biology. 7: 818-26. PMID 21946277 DOI: 10.1038/Nchembio.670  0.317
2011 Ruggiero A, Holland JP, Hudolin T, Shenker L, Koulova A, Bander NH, Lewis JS, Grimm J. Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 52: 1608-15. PMID 21908391 DOI: 10.2967/Jnumed.111.092098  0.35
2011 Zeglis BM, Mohindra P, Weissmann GI, Divilov V, Hilderbrand SA, Weissleder R, Lewis JS. Modular strategy for the construction of radiometalated antibodies for positron emission tomography based on inverse electron demand Diels-Alder click chemistry. Bioconjugate Chemistry. 22: 2048-59. PMID 21877749 DOI: 10.1021/Bc200288D  0.35
2011 Zeglis BM, Pillarsetty N, Divilov V, Blasberg RA, Lewis JS. The synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), a PET radiotracer designed for the delineation of histone deacetylase expression in cancer. Nuclear Medicine and Biology. 38: 683-96. PMID 21718944 DOI: 10.1016/J.Nucmedbio.2010.12.008  0.329
2011 Rice SL, Roney CA, Daumar P, Lewis JS. The next generation of positron emission tomography radiopharmaceuticals in oncology Seminars in Nuclear Medicine. 41: 265-282. PMID 21624561 DOI: 10.1053/J.Semnuclmed.2011.02.002  0.367
2011 Holland JP, Normand G, Ruggiero A, Lewis JS, Grimm J. Intraoperative imaging of positron emission tomographic radiotracers using Cerenkov luminescence emissions. Molecular Imaging. 10: 177-86, 1-3. PMID 21496448 DOI: 10.2310/7290.2010.00047S  0.419
2011 Zeglis BM, Lewis JS. A practical guide to the construction of radiometallated bioconjugates for positron emission tomography. Dalton Transactions (Cambridge, England : 2003). 40: 6168-95. PMID 21442098 DOI: 10.1039/C0Dt01595D  0.405
2011 Heneweer C, Holland JP, Divilov V, Carlin S, Lewis JS. Magnitude of enhanced permeability and retention effect in tumors with different phenotypes: 89Zr-albumin as a model system. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 52: 625-633. PMID 21421727 DOI: 10.2967/Jnumed.110.083998  0.34
2011 Zeglis BM, Divilov V, Lewis JS. Role of metalation in the topoisomerase IIα inhibition and antiproliferation activity of a series of α-heterocyclic-N4-substituted thiosemicarbazones and their Cu(II) complexes. Journal of Medicinal Chemistry. 54: 2391-8. PMID 21391686 DOI: 10.1021/Jm101532U  0.305
2011 Arrowsmith RL, Zeglis BM, Viola-Villegas N, Divilov, Jones M, Waghorn PA, Phillips FL, Mindt TL, Eggleston IM, Botchway SW, Dilworth JR, Aigbirhio FI, Lewis JS, Pascu SI. Fluorescent copper(II), gallium(III) and indium(III) bis(thiosemicarbazonates):Radiolabeling, cellular confocal fluorescence and PET imaging studies Journal of Labelled Compounds and Radiopharmaceuticals. 54. DOI: 10.1002/Jlcr.1925  0.326
2010 Ruggiero A, Villa CH, Holland JP, Sprinkle SR, May C, Lewis JS, Scheinberg DA, McDevitt MR. Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes. International Journal of Nanomedicine. 5: 783-802. PMID 21042424 DOI: 10.2147/Ijn.S13300  0.399
2010 Ruggiero A, Holland JP, Lewis JS, Grimm J. Cerenkov luminescence imaging of medical isotopes. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 51: 1123-30. PMID 20554722 DOI: 10.2967/Jnumed.110.076521  0.358
2010 Holland JP, Williamson MJ, Lewis JS. Unconventional nuclides for radiopharmaceuticals. Molecular Imaging. 9: 1-20. PMID 20128994 DOI: 10.2310/7290.2010.00008  0.333
2010 Bonnitcha PD, Bayly SR, Theobald MB, Betts HM, Lewis JS, Dilworth JR. Nitroimidazole conjugates of bis(thiosemicarbazonato)64Cu(II) - Potential combination agents for the PET imaging of hypoxia. Journal of Inorganic Biochemistry. 104: 126-35. PMID 19932509 DOI: 10.1016/J.Jinorgbio.2009.10.009  0.411
2009 Holland JP, Ferdani R, Anderson CJ, Lewis JS. Copper-64 Radiopharmaceuticals for Oncologic Imaging. Pet Clinics. 4: 49-67. PMID 27156895 DOI: 10.1016/J.Cpet.2009.04.013  0.389
2009 Holland JP, Sheh Y, Lewis JS. Standardized methods for the production of high specific-activity zirconium-89. Nuclear Medicine and Biology. 36: 729-39. PMID 19720285 DOI: 10.1016/J.Nucmedbio.2009.05.007  0.366
2009 Wei L, Zhang X, Gallazzi F, Miao Y, Jin X, Brechbiel MW, Xu H, Clifford T, Welch MJ, Lewis JS, Quinn TP. Melanoma imaging using (111)In-, (86)Y- and (68)Ga-labeled CHX-A''-Re(Arg11)CCMSH. Nuclear Medicine and Biology. 36: 345-54. PMID 19423001 DOI: 10.1016/J.Nucmedbio.2009.01.007  0.495
2009 V?vere AL, Biddlecombe GB, Spees WM, Garbow JR, Wijesinghe D, Andreev OA, Engelman DM, Reshetnyak YK, Lewis JS. A novel technology for the imaging of acidic prostate tumors by positron emission tomography. Cancer Research. 69: 4510-6. PMID 19417132 DOI: 10.1158/0008-5472.Can-08-3781  0.38
2009 Dunphy MP, Lewis JS. Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 106S-21S. PMID 19380404 DOI: 10.2967/Jnumed.108.057281  0.385
2009 Wei L, Ye Y, Wadas TJ, Lewis JS, Welch MJ, Achilefu S, Anderson CJ. (64)Cu-labeled CB-TE2A and diamsar-conjugated RGD peptide analogs for targeting angiogenesis: comparison of their biological activity. Nuclear Medicine and Biology. 36: 277-85. PMID 19324273 DOI: 10.1016/J.Nucmedbio.2008.12.008  0.507
2009 Zhou D, Zhou H, Jenks CC, Lewis JS, Katzenellenbogen JA, Welch MJ. Bromination from the macroscopic level to the tracer radiochemical level: (76)Br radiolabeling of aromatic compounds via electrophilic substitution. Bioconjugate Chemistry. 20: 808-16. PMID 19260733 DOI: 10.1021/Bc800313C  0.447
2009 Schneider DW, Heitner T, Alicke B, Light DR, McLean K, Satozawa N, Parry G, Yoo J, Lewis JS, Parry R. In vivo biodistribution, PET imaging, and tumor accumulation of 86Y- and 111In-antimindin/RG-1, engineered antibody fragments in LNCaP tumor-bearing nude mice. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 50: 435-43. PMID 19223400 DOI: 10.2967/Jnumed.108.055608  0.365
2009 Papini G, Alidori S, Lewis JS, Reichert DE, Pellei M, Gioia Lobbia G, Biddlecombe GB, Anderson CJ, Santini C. Synthesis and characterization of the copper(II) complexes of new N2S2-donor macrocyclic ligands: synthesis and in vivo evaluation of the (64)Cu complexes. Dalton Transactions (Cambridge, England : 2003). 177-84. PMID 19081987 DOI: 10.1039/B808831D  0.322
2009 Choi JC, Hausner SH, Gagnon MKJ, Kukis DL, Holland JP, Lewis JS, Lin C, Johnson MD, Sutcliffe JL. Abstract A227: Positron emission tomographic (PET) imaging of activated matriptase, a marker for cancer progression Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-A227  0.421
2009 Holland JP, Caldas‐Lopes E, Divilov V, Longo VA, Taldone T, Zatorska D, Chiosis G, Lewis JS. Abstract A226: ImmunoPET with 89Zr‐DFO‐trastuzumab: Monitoring the pharmacodynamic effects on HER2/neu expression by Hsp90 inhibition in vivo Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-A226  0.334
2009 Holland JP, Jones MW, Bonnitcha PD, Lewis JS, Dilworth JR. Functionalised copper-64 complexes as precursors of potential PET imaging agents for neurodegenerative disorders New Journal of Chemistry. 33: 1845-1852. DOI: 10.1039/B902895A  0.361
2008 Dietz DW, Dehdashti F, Grigsby PW, Malyapa RS, Myerson RJ, Picus J, Ritter J, Lewis JS, Welch MJ, Siegel BA. Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Diseases of the Colon and Rectum. 51: 1641-8. PMID 18682881 DOI: 10.1007/S10350-008-9420-3  0.528
2008 Dence CS, Ponde DE, Welch MJ, Lewis JS. Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer. Nuclear Medicine and Biology. 35: 713-20. PMID 18678357 DOI: 10.1016/J.Nucmedbio.2008.06.001  0.524
2008 Zhou D, Sharp TL, Fettig NM, Lee H, Lewis JS, Katzenellenbogen JA, Welch MJ. Evaluation of a bromine-76-labeled progestin 16alpha,17alpha-dioxolane for breast tumor imaging and radiotherapy: in vivo biodistribution and metabolic stability studies. Nuclear Medicine and Biology. 35: 655-63. PMID 18678350 DOI: 10.1016/J.Nucmedbio.2008.05.001  0.433
2008 Lewis JS, Laforest R, Dehdashti F, Grigsby PW, Welch MJ, Siegel BA. An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 49: 1177-82. PMID 18552145 DOI: 10.2967/Jnumed.108.051326  0.55
2008 Bonnitcha PD, Vāvere AL, Lewis JS, Dilworth JR. In vitro and in vivo evaluation of bifunctional bisthiosemicarbazone 64Cu-complexes for the positron emission tomography imaging of hypoxia. Journal of Medicinal Chemistry. 51: 2985-91. PMID 18416544 DOI: 10.1021/Jm800031X  0.728
2008 Vāvere AL, Lewis JS. Examining the relationship between Cu-ATSM hypoxia selectivity and fatty acid synthase expression in human prostate cancer cell lines. Nuclear Medicine and Biology. 35: 273-9. PMID 18355682 DOI: 10.1016/J.Nucmedbio.2007.11.012  0.715
2008 Vāvere AL, Kridel SJ, Wheeler FB, Lewis JS. 1-11C-acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 49: 327-34. PMID 18199615 DOI: 10.2967/Jnumed.107.046672  0.687
2008 Dehdashti F, Grigsby PW, Lewis JS, Laforest R, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone). Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 49: 201-5. PMID 18199612 DOI: 10.2967/Jnumed.107.048520  0.562
2008 Lu W, Li H, Lewis J, Thorstad W, Low D, Laforest R, Nussenbaum B, Zhu J, Parikh P, Wu B, Biehl K. SU-GG-J-03: 3D Pathology Validation for Head-And-Neck Tumor Segmentation in PET/CT/MRI Images Medical Physics. 35: 2679-2679. DOI: 10.1118/1.2961560  0.386
2007 Lewis JS, Anderson CJ. Radiometal-labeled somatostatin analogs for applications in cancer imaging and therapy. Methods in Molecular Biology (Clifton, N.J.). 386: 227-40. PMID 18604948 DOI: 10.1007/978-1-59745-430-8_8  0.372
2007 Alidori S, Gioia Lobbia G, Papini G, Pellei M, Porchia M, Refosco F, Tisato F, Lewis JS, Santini C. Synthesis, in vitro and in vivo characterization of (64)Cu(I) complexes derived from hydrophilic tris(hydroxymethyl)phosphane and 1,3,5-triaza-7-phosphaadamantane ligands. Journal of Biological Inorganic Chemistry : Jbic : a Publication of the Society of Biological Inorganic Chemistry. 13: 307-15. PMID 18043951 DOI: 10.1007/S00775-007-0322-Y  0.386
2007 Wei L, Miao Y, Gallazzi F, Quinn TP, Welch MJ, Vāvere AL, Lewis JS. Gallium-68-labeled DOTA-rhenium-cyclized alpha-melanocyte-stimulating hormone analog for imaging of malignant melanoma. Nuclear Medicine and Biology. 34: 945-53. PMID 17998097 DOI: 10.1016/J.Nucmedbio.2007.07.003  0.765
2007 Vāvere AL, Lewis JS. Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia. Dalton Transactions (Cambridge, England : 2003). 4893-902. PMID 17992274 DOI: 10.1039/B705989B  0.703
2007 Biddlecombe GB, Rogers BE, de Visser M, Parry JJ, de Jong M, Erion JL, Lewis JS. Molecular imaging of gastrin-releasing peptide receptor-positive tumors in mice using 64Cu- and 86Y-DOTA-(Pro1,Tyr4)-bombesin(1-14). Bioconjugate Chemistry. 18: 724-30. PMID 17378600 DOI: 10.1021/Bc060281L  0.454
2007 Jost SC, Wanebo JE, Song SK, Chicoine MR, Rich KM, Woolsey TA, Lewis JS, Mach RH, Xu J, Garbow JR. In vivo imaging in a murine model of glioblastoma. Neurosurgery. 60: 360-70; discussion 3. PMID 17290188 DOI: 10.1227/01.Neu.0000249264.80579.37  0.399
2007 Wei L, Butcher C, Miao Y, Gallazzi F, Quinn TP, Welch MJ, Lewis JS. Synthesis and biologic evaluation of 64Cu-labeled rhenium-cyclized alpha-MSH peptide analog using a cross-bridged cyclam chelator. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 48: 64-72. PMID 17204700  0.428
2007 Padhani AR, Krohn KA, Lewis JS, Alber M. Imaging oxygenation of human tumours. European Radiology. 17: 861-72. PMID 17043737 DOI: 10.1007/S00330-006-0431-Y  0.36
2006 Tatum JL, Kelloff GJ, Gillies RJ, Arbeit JM, Brown JM, Chao KS, Chapman JD, Eckelman WC, Fyles AW, Giaccia AJ, Hill RP, Koch CJ, Krishna MC, Krohn KA, Lewis JS, et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. International Journal of Radiation Biology. 82: 699-757. PMID 17118889 DOI: 10.1080/09553000601002324  0.357
2006 Clifford T, Boswell CA, Biddlecombe GB, Lewis JS, Brechbiel MW. Validation of a novel CHX-A'' derivative suitable for peptide conjugation: small animal PET/CT imaging using yttrium-86-CHX-A''-octreotide. Journal of Medicinal Chemistry. 49: 4297-304. PMID 16821789 DOI: 10.1021/Jm060317V  0.367
2006 Welch MJ, Lewis JS, Kim J, Sharp TL, Dence CS, Gropler RJ, Herrero P. Assessment of myocardial metabolism in diabetic rats using small-animal PET: a feasibility study. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 47: 689-97. PMID 16595504  0.37
2006 Ruangma A, Bai B, Lewis JS, Sun X, Welch MJ, Leahy R, Laforest R. Three-dimensional maximum a posteriori (MAP) imaging with radiopharmaceuticals labeled with three Cu radionuclides. Nuclear Medicine and Biology. 33: 217-26. PMID 16546676 DOI: 10.1016/J.Nucmedbio.2005.11.001  0.511
2006 Silva MJ, Uthgenannt BA, Rutlin JR, Wohl GR, Lewis JS, Welch MJ. In vivo skeletal imaging of 18F-fluoride with positron emission tomography reveals damage- and time-dependent responses to fatigue loading in the rat ulna. Bone. 39: 229-36. PMID 16533624 DOI: 10.1016/J.Bone.2006.01.149  0.447
2006 Herrero P, Kim J, Sharp TL, Engelbach JA, Lewis JS, Gropler RJ, Welch MJ. Assessment of myocardial blood flow using 15O-water and 1-11C-acetate in rats with small-animal PET. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 47: 477-85. PMID 16513617  0.331
2006 Kim J, Herrero P, Sharp T, Laforest R, Rowland DJ, Tai YC, Lewis JS, Welch MJ. Minimally invasive method of determining blood input function from PET images in rodents. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 47: 330-6. PMID 16455640  0.407
2005 Yoo J, Tang L, Perkins TA, Rowland DJ, Laforest R, Lewis JS, Welch MJ. Preparation of high specific activity (86)Y using a small biomedical cyclotron. Nuclear Medicine and Biology. 32: 891-7. PMID 16253815 DOI: 10.1016/J.Nucmedbio.2005.06.007  0.431
2005 Laforest R, Sharp TL, Engelbach JA, Fettig NM, Herrero P, Kim J, Lewis JS, Rowland DJ, Tai YC, Welch MJ. Measurement of input functions in rodents: challenges and solutions. Nuclear Medicine and Biology. 32: 679-85. PMID 16243642 DOI: 10.1016/J.Nucmedbio.2005.06.012  0.46
2005 Parry R, Schneider D, Hudson D, Parkes D, Xuan JA, Newton A, Toy P, Lin R, Harkins R, Alicke B, Biroc S, Kretschmer PJ, Halks-Miller M, Klocker H, Zhu Y, ... ... Lewis JS, et al. Identification of a novel prostate tumor target, mindin/RG-1, for antibody-based radiotherapy of prostate cancer. Cancer Research. 65: 8397-405. PMID 16166318 DOI: 10.1158/0008-5472.Can-05-1203  0.372
2005 Burgman P, O'Donoghue JA, Lewis JS, Welch MJ, Humm JL, Ling CC. Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM. Nuclear Medicine and Biology. 32: 623-30. PMID 16026709 DOI: 10.1016/J.Nucmedbio.2005.05.003  0.489
2005 McQuade P, Rowland DJ, Lewis JS, Welch MJ. Positron-emitting isotopes produced on biomedical cyclotrons. Current Medicinal Chemistry. 12: 807-18. PMID 15853713 DOI: 10.2174/0929867053507397  0.479
2005 McQuade P, Miao Y, Yoo J, Quinn TP, Welch MJ, Lewis JS. Imaging of melanoma using 64Cu- and 86Y-DOTA-ReCCMSH(Arg11), a cyclized peptide analogue of alpha-MSH. Journal of Medicinal Chemistry. 48: 2985-92. PMID 15828837 DOI: 10.1021/Jm0490282  0.576
2005 O'Donoghue JA, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S, Burnazi E, Finn RD, Burgman P, Ruan S, Lewis JS, Welch MJ, Ling CC, Humm JL. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. International Journal of Radiation Oncology, Biology, Physics. 61: 1493-502. PMID 15817355 DOI: 10.1016/J.Ijrobp.2004.12.057  0.568
2005 Laforest R, Dehdashti F, Lewis JS, Schwarz SW. Dosimetry of 60/61/62/64Cu-ATSM: a hypoxia imaging agent for PET. European Journal of Nuclear Medicine and Molecular Imaging. 32: 764-70. PMID 15785955 DOI: 10.1007/S00259-004-1756-X  0.373
2005 McQuade P, Martin KE, Castle TC, Went MJ, Blower PJ, Welch MJ, Lewis JS. Investigation into 64Cu-labeled Bis(selenosemicarbazone) and Bis(thiosemicarbazone) complexes as hypoxia imaging agents. Nuclear Medicine and Biology. 32: 147-56. PMID 15721760 DOI: 10.1016/J.Nucmedbio.2004.10.004  0.532
2005 Obata A, Kasamatsu S, Lewis JS, Furukawa T, Takamatsu S, Toyohara J, Asai T, Welch MJ, Adams SG, Saji H, Yonekura Y, Fujibayashi Y. Basic characterization of 64Cu-ATSM as a radiotherapy agent. Nuclear Medicine and Biology. 32: 21-8. PMID 15691658 DOI: 10.1016/J.Nucmedbio.2004.08.012  0.49
2004 Obata A, Yoshimoto M, Kasamatsu S, Naiki H, Takamatsu S, Kashikura K, Furukawa T, Lewis JS, Welch MJ, Saji H, Yonekura Y, Fujibayashi Y. Intra-tumoral distribution of (64)Cu-ATSM: a comparison study with FDG. Nuclear Medicine and Biology. 30: 529-34. PMID 12831991 DOI: 10.1016/S0969-8051(03)00047-7  0.551
2004 Herrero P, Kim J, Sharp T, Dence C, Lewis JS, Gropler RJ, Welch MJ. 1116-24 Assessment of myocardial perfusion and metabolism in normal and diabetic rats by microPET imaging Journal of the American College of Cardiology. 43: A25. DOI: 10.1016/S0735-1097(04)90103-9  0.43
2004 Schwarz J, Kim E, Malyapa R, Grigsby P, Lewis J, Higashikubo R, Horikoshi N, Huettner P, Dehdashti F, Mintun M, Siegel B, Welch M. Oncologic imaging of tumor hypoxia by Cu-ATSM and correlating findings on Cu-ATSM PET scans to cellular markers that may predict for radiation response International Journal of Radiation Oncology*Biology*Physics. 60: S305-S306. DOI: 10.1016/J.Ijrobp.2004.07.109  0.542
2003 Aft RL, Lewis JS, Zhang F, Kim J, Welch MJ. Enhancing targeted radiotherapy by copper(II)diacetyl- bis(N4-methylthiosemicarbazone) using 2-deoxy-D-glucose. Cancer Research. 63: 5496-504. PMID 14500386  0.486
2003 Mathias CJ, Lewis MR, Reichert DE, Laforest R, Sharp TL, Lewis JS, Yang ZF, Waters DJ, Snyder PW, Low PS, Welch MJ, Green MA. Preparation of 66Ga- and 68Ga-labeled Ga(III)-deferoxamine-folate as potential folate-receptor-targeted PET radiopharmaceuticals. Nuclear Medicine and Biology. 30: 725-31. PMID 14499330 DOI: 10.1016/S0969-8051(03)00080-5  0.483
2003 Welch MJ, Lewis JS. [Tc(CO)(3)](+) chemistry: a promising new concept for SPECT? Against. European Journal of Nuclear Medicine and Molecular Imaging. 30: 1302-4. PMID 12898205 DOI: 10.1007/S00259-003-1293-Z  0.402
2003 Scappaticci FA, Contreras A, Boswell CA, Lewis JS, Nolan G. Polyclonal antibodies to xenogeneic endothelial cells induce apoptosis and block support of tumor growth in mice. Vaccine. 21: 2667-77. PMID 12744904 DOI: 10.1016/S0264-410X(02)00693-X  0.361
2003 Dehdashti F, Mintun MA, Lewis JS, Bradley J, Govindan R, Laforest R, Welch MJ, Siegel BA. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. European Journal of Nuclear Medicine and Molecular Imaging. 30: 844-50. PMID 12692685 DOI: 10.1007/S00259-003-1130-4  0.555
2003 Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. International Journal of Radiation Oncology, Biology, Physics. 55: 1233-8. PMID 12654432 DOI: 10.1016/S0360-3016(02)04477-2  0.546
2003 Rowland DJ, Lewis JS, Welch MJ. Molecular imaging: the application of small animal positron emission tomography. Journal of Cellular Biochemistry. Supplement. 39: 110-5. PMID 12552610 DOI: 10.1002/Jcb.10417  0.516
2003 Lewis JS, Connett J, Ye D, Dehdashti F, Grigsby P, Mintun MA, Laforest R, Welch MJ. Po-topic IV-01 Academic Radiology. 10: 953-954. DOI: 10.1016/S1076-6332(03)00037-0  0.378
2002 Lewis JS, Herrero P, Sharp TL, Engelbach JA, Fujibayashi Y, Laforest R, Kovacs A, Gropler RJ, Welch MJ. Delineation of hypoxia in canine myocardium using PET and copper(II)-diacetyl-bis(N(4)-methylthiosemicarbazone). Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 43: 1557-69. PMID 12411560  0.408
2002 Lewis JS, Achilefu S, Garbow JR, Laforest R, Welch MJ. Small animal imaging: Current technology and perspectives for oncological imaging European Journal of Cancer. 38: 2173-2188. PMID 12387842 DOI: 10.1016/S0959-8049(02)00394-5  0.481
2002 Li WP, Lewis JS, Kim J, Bugaj JE, Johnson MA, Erion JL, Anderson CJ. DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy. Bioconjugate Chemistry. 13: 721-8. PMID 12121126 DOI: 10.1021/Bc015590K  0.412
2002 Dearling JL, Lewis JS, Mullen GE, Welch MJ, Blower PJ. Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships. Journal of Biological Inorganic Chemistry : Jbic : a Publication of the Society of Biological Inorganic Chemistry. 7: 249-59. PMID 11935349 DOI: 10.1007/S007750100291  0.517
2002 Lewis JS, Connett JM, Garbow JR, Buettner TL, Fujibayashi Y, Fleshman JW, Welch MJ. Copper-64-pyruvaldehyde-bis(N4-methylthiosemicarbazone) for the prevention of tumor growth at wound sites following laparoscopic surgery: Monitoring therapy response with microPET and magnetic resonance imaging Cancer Research. 62: 445-449. PMID 11809694  0.455
2002 Chao K, Bosch WR, Malyapa R, Lewis JS, Dehdashti F, Welch MJ. Evolution of tumor hypoxia during radiotherapy predicts treatment response: implication of hypoxic imaging-guided IMRT International Journal of Radiation Oncology Biology Physics. 54: 72-73. DOI: 10.1016/S0360-3016(02)03182-6  0.493
2001 Obata A, Yoshimi E, Waki A, Lewis JS, Oyama N, Welch MJ, Saji H, Yonekura Y, Fujibayashi Y. Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent Cu-diacetyl-bis( N 4 -methylthiosemicarbazone) (Cu-ATSM) in tumor cells Annals of Nuclear Medicine. 15: 499-504. PMID 11831397 DOI: 10.1007/Bf02988502  0.526
2001 Lewis JS, Wang M, Laforest R, Wang F, Erion JL, Bugaj JE, Srinivasan A, Anderson CJ. Toxicity and dosimetry of 177Lu-DOTA-Y3-octreotate in a rat model International Journal of Cancer. 94: 873-877. PMID 11745491 DOI: 10.1002/Ijc.1540  0.324
2001 Chao KS, Bosch WR, Mutic S, Lewis JS, Dehdashti F, Mintun MA, Dempsey JF, Perez CA, Purdy JA, Welch MJ. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. International Journal of Radiation Oncology, Biology, Physics. 49: 1171-82. PMID 11240261 DOI: 10.1016/S0360-3016(00)01433-4  0.554
2001 Lewis JS, Laforest R, Buettner TL, Song SK, Fujibayashi Y, Connett JM, Welch MJ. Copper-64-diacetyl-bis(N4-methylthiosemicarbazone): An agent for radiotherapy Proceedings of the National Academy of Sciences of the United States of America. 98: 1206-1211. PMID 11158618 DOI: 10.1073/Pnas.98.3.1206  0.516
2001 Chao KS, Bosch WR, Mutic S, Lewis JS, Dehdashti F, Mintun MA, Dempsey JF, Perez CA, Purdy JA, Welch MJ. A prospective study on tumor hypoxia kinetics to implement hypoxic imaging-guided IMRT International Journal of Radiation Oncology Biology Physics. 51: 83. DOI: 10.1016/S0360-3016(01)01977-0  0.513
2001 Lewis JS, Connett JM, Garbow JR, Buettner TL, Fujibayashi Y, Fleshman JW, Welch MJ. 64Cu-PTSM as an inhibitor of tumor recurrence Journal of Labelled Compounds and Radiopharmaceuticals. 44: S87-S89. DOI: 10.1002/Jlcr.2580440130  0.499
2000 Lewis JS, Laforest R, Lewis MR, Anderson CJ. Comparative dosimetry of copper-64 and yttrium-90-labeled somatostatin analogs in a tumor-bearing rat model. Cancer Biotherapy & Radiopharmaceuticals. 15: 593-604. PMID 11190491 DOI: 10.1089/Cbr.2000.15.593  0.34
2000 Lewis JS, Dearling JL, Sosabowski JK, Zweit J, Carnochan P, Kelland LR, Coley HM, Blower PJ. Copper bis(diphosphine) complexes: radiopharmaceuticals for the detection of multi-drug resistance in tumours by PET. European Journal of Nuclear Medicine. 27: 638-46. PMID 10901449 DOI: 10.1007/S002590050557  0.379
2000 Anderson CJ, Lewis JS. Radiopharmaceuticals for targeted radiotherapy of cancer Expert Opinion On Therapeutic Patents. 10: 1057-1069. DOI: 10.1517/13543776.10.7.1057  0.306
1999 McCarthy DW, Bass LA, Cutler PD, Shefer RE, Klinkowstein RE, Herrero P, Lewis JS, Cutler CS, Anderson CJ, Welch MJ. High purity production and potential applications of copper-60 and copper-61. Nuclear Medicine and Biology. 26: 351-8. PMID 10382836 DOI: 10.1016/S0969-8051(98)00113-9  0.504
1999 Lewis JS, Srinivasan A, Schmidt MA, Anderson CJ. In vitro and in vivo evaluation of 64Cu-TETA-Tyr3-octreotate. A new somatostatin analog with improved target tissue uptake. Nuclear Medicine and Biology. 26: 267-73. PMID 10363797 DOI: 10.1016/S0969-8051(98)00105-X  0.424
1999 Lewis JS, Lewis MR, Srinivasan A, Schmidt MA, Wang J, Anderson CJ. Comparison of four 64Cu-labeled somatostatin analogues in vitro and in a tumor-bearing rat model: evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy. Journal of Medicinal Chemistry. 42: 1341-7. PMID 10212119 DOI: 10.1021/Jm980602H  0.4
1999 Reichert DE, Lewis JS, Anderson CJ. Metal complexes as diagnostic tools Coordination Chemistry Reviews. 184: 3-66. DOI: 10.1016/S0010-8545(98)00207-0  0.351
1998 Dearling JL, Lewis JS, Mullen GE, Rae MT, Zweit J, Blower PJ. Design of hypoxia-targeting radiopharmaceuticals: selective uptake of copper-64 complexes in hypoxic cells in vitro. European Journal of Nuclear Medicine. 25: 788-92. PMID 9662602 DOI: 10.1007/S002590050283  0.35
1998 Dearling JLJ, Lewis JS, McCarthy DW, Welch MJ, Blower PJ. Redox-active metal complexes for imaging hypoxic tissues: structure–activity relationships in copper(II) bis(thiosemicarbazone) complexes Chemical Communications. 2531-2532. DOI: 10.1039/A805957H  0.458
1996 Blower PJ, Lewis JS, Zweit J. Copper radionuclides and radiopharmaceuticals in nuclear medicine Nuclear Medicine and Biology. 23: 957-980. PMID 9004284 DOI: 10.1016/S0969-8051(96)00130-8  0.367
1996 Lewis JS, Zweit J, Dearling JLJ, Rooney BC, Blower PJ. Copper(I) bis(diphosphine) complexes as a basis for radiopharmaceuticals for positron emission tomography and targeted radiotherapy Chemical Communications. 1093-1094. DOI: 10.1039/Cc9960001093  0.382
Show low-probability matches.